Idera, Biocryst to merge, re­brand and fo­cus in rare dis­ease pro­grams

A few months af­ter Idera Phar­ma­ceu­ti­cals $IDRA stirred up some pos­i­tive buzz at ES­MO with ear­ly stage da­ta on its TLR9 pro­gram, the biotech an­nounced …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.